E Ardini

Summary

Affiliation: Nerviano Medical Sciences
Country: Italy

Publications

  1. doi request reprint Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
    Elena Ardini
    Nerviano Medical Sciences Srl, Nerviano, Milan, Italy
    Mol Cancer Ther 15:628-39. 2016
  2. doi request reprint The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
    Elena Ardini
    Nerviano Medical Sciences S r l, Nerviano Milan, Italy Electronic address
    Mol Oncol 8:1495-507. 2014
  3. pmc ALK Inhibitors, a Pharmaceutical Perspective
    Elena Ardini
    Department of Cell Biology, Oncology, Nerviano Medical Sciences Milan, Italy
    Front Oncol 2:17. 2012
  4. doi request reprint Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy
    E Ardini
    Department of Cell Biology, Oncology, Nerviano Medical Sciences S r l, Viale Pasteur 10, 20014 Nerviano, Milan, Italy
    Cancer Lett 299:81-94. 2010

Detail Information

Publications4

  1. doi request reprint Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
    Elena Ardini
    Nerviano Medical Sciences Srl, Nerviano, Milan, Italy
    Mol Cancer Ther 15:628-39. 2016
    ..Mol Cancer Ther; 15(4); 628-39. ©2016 AACR...
  2. doi request reprint The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
    Elena Ardini
    Nerviano Medical Sciences S r l, Nerviano Milan, Italy Electronic address
    Mol Oncol 8:1495-507. 2014
    ....
  3. pmc ALK Inhibitors, a Pharmaceutical Perspective
    Elena Ardini
    Department of Cell Biology, Oncology, Nerviano Medical Sciences Milan, Italy
    Front Oncol 2:17. 2012
    ..Here we discuss the factors that led to such a rapid approval of a targeted agent, and we describe the second-generation compounds currently in development...
  4. doi request reprint Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy
    E Ardini
    Department of Cell Biology, Oncology, Nerviano Medical Sciences S r l, Viale Pasteur 10, 20014 Nerviano, Milan, Italy
    Cancer Lett 299:81-94. 2010
    ..In this review, we describe the various oncogenic forms of ALK, relevant clinical settings, and give a detailed overview of current drug discovery efforts in the field...